Loading…
← CockpitCompetitor Analysis › LYEL Lyell Immunopharma, Inc.Open in the cockpit ↗

Lyell Immunopharma, Inc.LYELCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum strong 67
Mkt cap
$341M
US dollars, full cap
Free float
36%
of shares outstanding
$/day
$3.42M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$13.89
1D+1.6%
1W-17.6%
1M+43.2%
3M-9.5%
6M-19.3%
YTD-54.9%
1Y-20.3%
ATR %9.7%
Beta1.76
52w lowhigh69.1% off high

What Lyell Immunopharma does

Employees: 161

Lyell Immunopharma at a glance

Size Lyell Immunopharma (LYEL) is a United States Health Care company (Biotechnology) with a market value of $341M, the 2971st largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.89 on 18 Nov 2026.

Performance Over six months the shares fell 19.3%, against -31.0% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue fell 63.4% over the last twelve months (peer median +7.3%); the operating margin is -1,388,360.0% (peer median -115.0%).

Valuation It trades at 13,911.5× enterprise value to sales against a peer median of 5.3× (most expensive of 17).

Short interest Short interest is 5.7% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026LYEL 80Peer median 69
Six months, rebased to 100: Lyell Immunopharma against the median of its 20 peers (local-currency closes).

Lyell Immunopharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$15,000$36,000$61,000$130,000$84.7M
Revenue growth—-41%-53%-100%—
Gross profit-$8.99M-$11.5M-$19.6M-$20.1M$68.2M
EBITDA-$199M-$192M-$204M-$230M-$175M
Net income-$255M-$274M-$343M-$235M-$183M
Free cash flow-$140M-$151M-$163M-$166M-$194M
Capital expenditure$715,000$780,000$464,000$2.69M$24.3M
Total debt$44.3M$51.0M$59.0M$63.2M$67.7M

Quarterly statements and history in the cockpit →

Lyell Immunopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-25%0%+25%358570LRMR0869003880CRMD2105CCCCCTNM69457630476060PROKNAUT4894PRTCALECXFORLYEL6-month return →1-month return →
Up and to the right = strong over both horizons. Lyell Immunopharma is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×5,000×10,000×15,000×35857008690038807630476060PROK4894LYELRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lyell Immunopharma is the large dot.

Lyell Immunopharma competitors and peer comparison

How Lyell Immunopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lyell Immunopharma against its 20 peers (data as of 18 Nov 2026)
MeasureLYELPeer medianRank in peer set
1-month return+43.2%-4.7%highest of 20
6-month return-19.3%-31.0%8th highest of 20
Distance from 52-week high-69.1%-51.5%2nd lowest of 20
Revenue growth (TTM)-63.4%+7.3%2nd lowest of 15
Operating margin-1,388,360.0%-115.0%lowest of 17
EV / Sales13,911.5×5.3×most expensive of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%602.9×n/an/a
PureTech Health PRTC.LUnited Kingdom$378M-15%-4%-1,617%27.4×n/an/a
Alector ALECUnited States$383M+21%+151%25%1.5×n/an/a
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%11.4×n/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%1.0×2.6%+19.1%

Questions

Which companies are Lyell Immunopharma's closest peers?
The cockpit's peer set: GI Innovation (358570.KS), Larimar Therapeutics (LRMR), Aspen Neuroscience (ASPE), Medy-Tox (086900.KS), Medtide (3880.HK), CorMedix (CRMD), Laekna (2105.HK), C4 Therapeutics (CCCC).
Is Lyell Immunopharma expensive compared with its peers?
On ev / sales it trades at 13,911.5× against a peer median of 5.3×, most expensive of 17 in its peer set.
How has Lyell Immunopharma stock performed?
Over six months to 18 Nov 2026 the shares returned -19.3% against -31.0% for the median peer; over one year -20.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.